Eli Lilly CEO on WHO advising against using remdesivir to treat Covid-19

The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly's arthritis drug baricitinib, in combination with Gilead Sciences' remdesivir, to treat Covid-19 patients. On Thursday, a WHO panel advised doctors against using remdesivir as a treatment for patients hospitalized with Covid-19. David Ricks, Eli Lilly chairman and CEO, joins "Squawk Box" to discuss.
Fri, Nov 20 20208:48 AM EST